{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T18:18:10Z","timestamp":1766600290071,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T00:00:00Z","timestamp":1540512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202099"],"award-info":[{"award-number":["81202099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12282-018-0929-6","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T10:04:33Z","timestamp":1540548273000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database"],"prefix":"10.1007","volume":"26","author":[{"given":"Kejia","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-330X","authenticated-orcid":false,"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"issue":"2","key":"929_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"929_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"929_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/bjc.1988.139","volume":"57","author":"L Singh","year":"1988","unstructured":"Singh L, Wilson AJ, Baum M, Whimster WF, Birch IH, Jackson IM, Lowrey C, Palmer MK. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (\u2018Nolvadex\u2019) trial. Br J Cancer. 1988;57(6):612\u20134.","journal-title":"Br J Cancer"},{"issue":"9869","key":"929_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805\u201316.","journal-title":"Lancet"},{"issue":"12","key":"929_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135\u201341.","journal-title":"Lancet Oncol"},{"issue":"9472","key":"929_CR6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"(EBCTCG) EBCTCG","year":"2005","unstructured":"(EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet"},{"key":"929_CR7","first-page":"Cd004562","volume":"4","author":"S Goel","year":"2009","unstructured":"Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009;4:Cd004562.","journal-title":"Cochrane Database Syst Rev"},{"issue":"29","key":"929_CR8","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2011.36.4950","volume":"29","author":"JJ Griggs","year":"2011","unstructured":"Griggs JJ, Somerfield MR, Anderson H, Henry NL, Hudis CA, Khatcheressian JL, Partridge AH, Prestrud AA, Davidson NE. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol. 2011;29(29):3939\u201342.","journal-title":"J Clin Oncol"},{"issue":"5","key":"929_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"929_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107\u201318.","journal-title":"N Engl J Med"},{"issue":"19","key":"929_CR11","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","volume":"34","author":"MM Regan","year":"2016","unstructured":"Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Lang I, Gomez HL, Tondini C, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221\u201331.","journal-title":"J Clin Oncol"},{"issue":"8","key":"929_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ. Tailoring therapies\u2013improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533\u201346.","journal-title":"Ann Oncol"},{"issue":"14","key":"929_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","volume":"34","author":"HJ Burstein","year":"2016","unstructured":"Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689\u2013701.","journal-title":"J Clin Oncol"},{"issue":"7","key":"929_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","volume":"16","author":"J Bernhard","year":"2015","unstructured":"Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848\u201358.","journal-title":"Lancet Oncol"},{"issue":"7","key":"929_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679\u201391.","journal-title":"N Engl J Med"},{"issue":"2","key":"929_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10549-016-4024-4","volume":"161","author":"RT Chlebowski","year":"2017","unstructured":"Chlebowski RT, Pan K, Col NF. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. Breast Cancer Res Treat. 2017;161(2):185\u201390.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"929_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.amjmed.2008.09.030","volume":"122","author":"SL Silverman","year":"2009","unstructured":"Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114\u201320.","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"929_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1513\/AnnalsATS.201309-300RM","volume":"11","author":"N Roche","year":"2014","unstructured":"Roche N, Reddel H, Martin R, Brusselle G, Papi A, Thomas M, Postma D, Thomas V, Rand C, Chisholm A, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc. 2014;11(Suppl 2):99\u2013104.","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"929_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700\u20131712.","journal-title":"Ann Oncol"},{"issue":"25","key":"929_CR20","doi-asserted-by":"publisher","first-page":"e3865","DOI":"10.1097\/MD.0000000000003865","volume":"95","author":"Z Peng","year":"2016","unstructured":"Peng Z, Wei J, Lu X, Zheng H, Zhong X, Gao W, Chen Y, Jing J. Treatment and survival patterns of Chinese patients diagnosed with breast cancer between 2005 and 2009 in Southwest China: an observational, population-based cohort study. Medicine. 2016;95(25):e3865.","journal-title":"Medicine"},{"issue":"12","key":"929_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.6004\/jnccn.2015.0176","volume":"13","author":"WJ Gradishar","year":"2015","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al. NCCN guidelines insights breast cancer, version 1.2016. J Natl Compr Cancer Netw JNCCN. 2015;13(12):1475\u201385.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"5","key":"929_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdv106","volume":"26","author":"S Gourgou-Bourgade","year":"2015","unstructured":"Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A\u2019Hern R, Bliss J, Bogaerts J, Bonnefoi H, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. Ann Oncol. 2015;26(5):873\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"929_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"387","key":"929_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516\u201324.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"929_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jama.297.3.278","volume":"297","author":"TA Stukel","year":"2007","unstructured":"Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. Jama. 2007;297(3):278\u201385.","journal-title":"Jama"},{"issue":"7","key":"929_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","volume":"18","author":"A Goldhirsch","year":"2007","unstructured":"Goldhirsch A, Wood WC, Gelber RD, Coates AS, Th\u00fcrlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133\u201344.","journal-title":"Ann Oncol"},{"issue":"2","key":"929_CR27","doi-asserted-by":"publisher","first-page":"e0148849","DOI":"10.1371\/journal.pone.0148849","volume":"11","author":"C Xue","year":"2016","unstructured":"Xue C, Peng R, Cao Y, Wang S, Shi Y, An X, Xu F, Yuan Z. Ovarian function, not age, predicts the benefit from ovarian suppression or ablation for premenopausal women with breast cancer. PLoS One. 2016;11(2):e0148849.","journal-title":"PLoS One"},{"issue":"1","key":"929_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","volume":"63","author":"JLF Bosco","year":"2010","unstructured":"Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DSM, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64\u201374.","journal-title":"J Clin Epidemiol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0929-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-018-0929-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0929-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T21:08:04Z","timestamp":1572037684000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-018-0929-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,26]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s12282-018-0929-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"type":"print","value":"1340-6868"},{"type":"electronic","value":"1880-4233"}],"subject":[],"published":{"date-parts":[[2018,10,26]]},"assertion":[{"value":"3 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by Biomedical Research Ethics Committee (approval number: 2012130), West China Hospital, Sichuan University and performed in accordance with the ethical standards laid down in the 1964 declaration of Helsinki and all subsequent revisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The informed consents were obtained from all participants. Permissions were, therefore, obtained to collect and store their related information, and used for medical research. All patients\u2019 anonymity and privacy are carefully protected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}